Features | Partner Sites | Information | LinkXpress
Sign In
FLUKE BIOMEDICAL
Advantech Europe
SCHILLER AG

Special Glasses Help Surgeons Visualize Cancer

By HospiMedica International staff writers
Posted on 27 Feb 2014
Image: Breast surgeon Julie Margenthaler, MD, visualizing cancer cells (Photo courtesy of WUSTL - Washington University in St. Louis).
Image: Breast surgeon Julie Margenthaler, MD, visualizing cancer cells (Photo courtesy of WUSTL - Washington University in St. Louis).
High-tech glasses may help surgeons distinguish cancer cells from healthy cells by making them glow blue when viewed through the eyewear.

Developed by researchers at Washington University (St. Louis, MO, USA), the technology, called optical projection of acquired luminescence (OPAL), incorporates custom video technology, a head-mounted display, and a targeted molecular contrast agent that attaches to cancer cells, making them glow blue when irradiated with a special light. The resulting fluorescence intensity maps are projected onto the imaged surface and viewed through the glasses, rather than via wall-mounted display monitors.

To demonstrate the proof-of-principle for OPAL applications in oncologic surgery, lymphatic transport of indocyanine green was visualized in live mice for real-time identification of sentinel lymph nodes. Subsequently, peritoneal tumors in a murine model of breast cancer metastasis were identified using OPAL following systemic administration of a tumor-selective fluorescent molecular probe. The researchers noted that tumors as small as one mm in diameter could be detected. The study was published in the December 2013 issue of the Journal of Biomedical Optics.

“These initial results clearly show that OPAL can enhance adoption and ease-of-use of fluorescence imaging in oncologic procedures relative to existing state-of-the-art intraoperative imaging systems,” said lead author professor of radiology and biomedical engineering Samuel Achilefu, PhD. “This technology has great potential for patients and health-care professionals. Our goal is to make sure no cancer is left behind.”

“We’re in the early stages of this technology, and more development and testing will be done, but we’re certainly encouraged by the potential benefits to patients,” said associate professor of surgery Julie Margenthaler, MD, who performed the first in-human operation using the system at the WUSTL Barnes-Jewish Hospital (St. Louis, MO, USA) on February 10, 2014. “Imagine what it would mean if these glasses eliminated the need for follow-up surgery and the associated pain, inconvenience, and anxiety.”

Related Links:

Washington University
Barnes-Jewish Hospital



Channels

Critical Care

view channel
Image: The Evzio device and trainer (Photo courtesy of kaléo).

“Rescue Pen” Averts Opioid Overdose Risk

A novel autoinjector formulation of naloxone helps reduce the problem of addiction and abuse of prescription opioids. The Evzio pen is modeled on similar devices used deliver epinephrine to patients... Read more

Women's Health

view channel

Robotic-Assisted Hysterectomy Reduces Hospital Readmission

Women undergoing robotic-assisted hysterectomy are significantly less likely to be readmitted to a hospital than women receiving laparoscopic, open, or vaginal hysterectomy, according to a new study. Researchers at Lehigh Valley Health Network (Allentown, PA, USA) identified 2,554 women with benign disease who had undergone... Read more

Business

view channel

Infusion Pumps Propel Global Market Upwards

The global infusion pumps market is expected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching an estimated value of USD 7.8 billion in 2019. These are the latest findings of Transparency Market Research (Albany, NY, USA), a global market intelligence company. Infusion pumps are used to deliver therapeutic... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.